Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 498Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 190Stomach Neoplasms 183Esophageal Neoplasms 135Neoplasm Metastasis 98Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Neoplasms 44Cholangiocarcinoma 33Biliary Tract Neoplasms 27Adenocarcinoma 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Gallbladder Neoplasms 22Liver Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Bile Duct Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 16Ovarian Neoplasms 11Digestive System Neoplasms 10Colorectal Cancer Metastatic 10Carcinoma, Squamous Cell 10Peritoneal Neoplasms 9Breast Neoplasms 9Anal Canal Carcinoma 9Lung Neoplasms 8Head and Neck Neoplasms 8

Interventions

trifluridine tipiracil drug combination 1romidepsin 1futibatinib 1cabozantinib 1atezolizumab 1Trabectedin 1TAS-116 1Ramucirumab 1Imatinib Mesylate 1HhAntag691 1Gemcitabine 1Fluorouracil 1Dasatinib 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Fluorouracil × Gastrointestinal × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡